search icon
  • Print
  • ShareThis
  • Text Size


In order to contribute to the discussion forum you need to be an IDSA member. If you are an IDSA member, please login now. Please read our Discussion Forum Guidelines and Terms of Use before joining.

Hepatitis C

Welcome to Hepatitis C Management Discussion Board! The Hepatitis C Management Discussion Board provides Infectious Disease Clinicians a platform to connect with colleagues to exchange information, case studies, complications, and new developments on matters concerning hepatitis C treatment and management. Certain case studies will be developed into clinical vignettes and will be available to Infectious Disease Clinicians for future reference. Please be respectful of all participants and their respective comments. Please read our Terms of Use and Discussion Forum Guidelines.

 

Any diagnostic or therapeutic recommendations and all opinions presented are those of the individual contributor. They do not necessarily represent the views of IDSA. The reader assumes all risks in using this information. The IDSA Hepatitis C Discussion Forum is in full compliance with HIPPA. IDSA bears no responsibility for the accuracy of participant comments and will bear no legal liability for discussion results.

If a participant wishes to post an issue on the IDSA Hepatitis C Discussion Forum, the participant is strongly urged to provide contact information for possible offline discussion via phone or email concerning the posted issue.


RSS Feed Search Category View 
Drug Therapy
  Topics Topic Starter Replies Views Last Post
Spurred by pricey Gilead hep C drug, payers cook up new cost-control moves tkim@idsociety.org 0 9456 Monday, January 27, 2014 1:44 PM 
Simeprevir Earns Positive Internal Review from FDA ThomasKim 0 10054 Tuesday, October 22, 2013 1:33 PM 
Phase III Results for Gilead Hep C Combo tkim@idsociety.org 0 9570 Wednesday, December 18, 2013 12:51 PM 
More Drugs Show Promise in Fighting Hepatitis C - HealthDay Article ThomasKim 0 10624 Thursday, August 15, 2013 11:36 AM 
Merck Unveils Interim Phase II Results tkim@idsociety.org 0 8677 Thursday, April 10, 2014 1:46 PM 
Key hep C protein revealed, paving the way for new vaccines tkim@idsociety.org 0 9641 Wednesday, December 4, 2013 7:57 AM 
J&J, Medivir gain FDA OK for new hep C therapy simeprevir ThomasKim 0 9631 Monday, November 25, 2013 1:08 PM 
J&J, Gilead combo drug therapy clears hep C in 100% of Phase IIa cohort ThomasKim 0 13348 Monday, March 4, 2013 1:00 PM 
J&J wins FDA panel blessing for hep C blockbuster hopeful ThomasKim 0 9899 Friday, October 25, 2013 2:32 PM 
Indication and Usage of Olysio (simeprevir) for the Treatment of Chronic Hepatitis C ThomasKim 0 9604 Monday, November 25, 2013 2:38 PM 
Gilead's Sofosbuvir Gains FDA Panel Approval tkim@idsociety.org 0 10085 Monday, October 28, 2013 1:14 PM 
Gilead Successfully Completes Fourth Phase III Study tkim 0 12985 Tuesday, February 19, 2013 1:03 PM 
Gilead says payers feel comfortable with the cost of Sovaldi ThomasKim 0 9294 Friday, February 14, 2014 1:06 PM 
Gilead Passes Two Phase III Test with HCV Pill ThomasKim 0 13165 Monday, February 4, 2013 4:01 PM 
Gilead Next Generation Combination Pill ThomasKim 0 8876 Monday, March 24, 2014 1:01 PM 
Gilead gains FDA approval for hep C combo pill ThomasKim 0 4140 Monday, October 13, 2014 12:34 PM 
Gilead applies for FDA approval for Sofosbuvir ThomasKim 0 12925 Tuesday, April 9, 2013 1:36 PM 
FDA Internal Review of Sofosbuvir tkim@idsociety.org 0 10073 Wednesday, October 23, 2013 1:21 PM 
FDA approves Sovaldi for chronic hepatitis C ThomasKim 0 9644 Monday, December 9, 2013 10:21 AM 
FDA Approved Changes to Incivek (telaprevir) Product Labeling to Include OPTIMIZE Trial Results tkim@idsociety.org 0 10027 Wednesday, October 30, 2013 7:56 AM 
Clinicians Wait for Next Wave of Hepatitis C Antivirals - By: Debra Gordon tkim@idsociety.org 0 12081 Tuesday, June 11, 2013 3:43 PM 
Bristol-Myers Squibb Files for FDA Approval of NS5A Drug Combination tkim@idsociety.org 0 8660 Thursday, April 10, 2014 1:50 PM 
Bristol-Myers gains FDA breakthrough track for HCV drug approval tkim@idsociety.org 0 12906 Thursday, April 25, 2013 2:00 PM 
AbbVie Submits FDA Application for All Oral HCV Therapy tkim@idsociety.org 0 8745 Tuesday, April 22, 2014 1:52 PM 
AbbVie steps closer to FDA filing as first hep C PhIII delivers promising results tkim@idsociety.org 0 9696 Monday, November 18, 2013 1:45 PM 
AbbVie Announces Positive Phase III Results ThomasKim 0 8585 Friday, April 11, 2014 1:52 PM 
 

| HIVMA | Contact Us

© Copyright IDSA 2015 Infectious Diseases Society of America

Full Site Mobile Site